Bordetella pertussis

Whooping cough is surging in Australia. Why, and how can we protect ourselves?

Retrieved on: 
Friday, April 5, 2024
Sneeze, Pregnancy, Cough, Gene, COVID, Immunity, Disease, Pertactin, Risk, Patient, Bordetella pertussis, Ageing, Mouse, Social isolation, Bacteria, Respiratory tract infection, Life, Respiratory disease, Cold medicine, Woman, Fever, Atmosphere, Vaccination, Mask, Immune system, Rib, Vaccine

Cases are highest in Queensland and New South Wales, with more than 1,000 recorded in each state.

Key Points: 
  • Cases are highest in Queensland and New South Wales, with more than 1,000 recorded in each state.
  • The last time Queensland recorded more than 1,000 cases in three months was the first quarter of 2013.
  • So what is whooping cough, why are cases rising now, and how can you protect yourself?

It’s most dangerous for babies

  • The initial symptoms of whooping cough resemble other cold and flu-like symptoms.
  • However, as the disease progresses into the second week, the coughing fits become worse and more frequent.
  • After or between bouts of coughing, patients may gasp for air and produce the characteristic “whoop” noise.
  • Immunity from these vaccines wanes over time, so it’s also recommended adults receive a booster, particularly those who may come into frequent contact with babies.

Why are cases rising now?

  • Due to COVID measures such as border closures, social isolation and masks, the number of cases declined dramatically during 2020–23.
  • In Australia, cases have been particularly high during this outbreak in children aged 10–14.

A potential superbug

  • Most vaccines used in Australia and other developed countries stimulate your immune system to recognise and target three to five components of the bacteria.
  • These mutations make the bacteria look slightly different to the one used in the vaccine, helping it better hide from the immune system.
  • But in 2008, a new strain appeared in Australia that no longer produced pertactin, one of the components targeted by the vaccine.
  • This means your immune system, like a detective, has one less clue to recognise the bacteria.
  • Read more:
    Low vaccination and immunity rates mean NZ faces a harsh whooping cough winter – what needs to happen

What next?

  • Greater tracking of whooping cough strains, like we do with COVID, is needed to inform future vaccine design and treatments.
  • Importantly, although the bacteria is evolving, current vaccines are still very effective at preventing serious disease and reducing transmission.


Laurence Don Wai Luu does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

ILiAD Biotechnologies Announces Presentation at the 2023 World Vaccine Congress in Barcelona

Retrieved on: 
Wednesday, October 18, 2023
Biotechnology, General Health, Infectious Diseases, Health, Pharmaceutical, Infection, Bordetella pertussis, Fast track (FDA), Cold medicine, MPH, Iliad, Vaccine, MD

ILiAD Biotechnologies, LLC (ILiAD), a vaccine company utilizing its B-Tech technology to develop novel vaccines against infectious diseases, today announced Chief Medical Officer Stephanie Noviello, MD, MPH, will present data on its pertussis vaccine, BPZE1, at the World Vaccine Congress Europe in Barcelona, Spain (October 17 – 19, 2023).

Key Points: 
  • ILiAD Biotechnologies, LLC (ILiAD), a vaccine company utilizing its B-Tech technology to develop novel vaccines against infectious diseases, today announced Chief Medical Officer Stephanie Noviello, MD, MPH, will present data on its pertussis vaccine, BPZE1, at the World Vaccine Congress Europe in Barcelona, Spain (October 17 – 19, 2023).
  • BPZE1 is the most advanced next generation pertussis vaccine, designed to overcome deficiencies of current vaccines which include limited durability and the inability to prevent nasopharyngeal Bordetella pertussis infections that lead to transmission, especially to vulnerable infants.
  • Data from four BPZE1 human clinical studies have previously been published and BPZE1 has received FDA Fast Track designation.
  • Title: BPZE1, an intranasal live attenuated pertussis vaccine, evaluated in a Bordetella pertussis challenge study in healthy adults: a phase 2b, randomized, placebo-controlled study
    A copy of the presentation will be available after the conclusion of the meeting in the “BPZE1 Publications” section of the ILiAD website.

Intravacc announces publication of In Vitro alternative to replace animal pyrogen test for vaccines

Retrieved on: 
Tuesday, September 19, 2023
Vaccine, Public, Immunity, Research, MAT, Animal, OMV, Scientific Reports, Bordetella pertussis, RPT

However, vaccine safety is of paramount importance, and researchers are continually exploring innovative methods to ensure that new vaccines are both effective and safe.

Key Points: 
  • However, vaccine safety is of paramount importance, and researchers are continually exploring innovative methods to ensure that new vaccines are both effective and safe.
  • The MAT is an in vitro assay that can replace the rabbit pyrogen test.
  • The article entitled “In vitro alternative for reactogenicity assessment of outer membrane vesicle based vaccines” is published in the peer reviewed journal of Scientific Reports, volume 13, 2023.
  • The MAT also proved its applicability to assess reactogenicity levels of pyrogen containing vaccines at multiple stages of vaccine development and could eventually replace RPT.

ILiAD Biotechnologies Reports First-ever Demonstration of Protection Against B. pertussis Colonization in Phase 2b Human Challenge Study of BPZE1 Vaccine

Retrieved on: 
Tuesday, September 5, 2023
Other Health, Research, General Health, Pharmaceutical, Infectious Diseases, Hospitals, Clinical Trials, Science, Biotechnology, FDA, Other Science, Health, Vaccine, Bordetella pertussis, Cold medicine, University Hospital Southampton NHS Foundation Trust, University, Vaccination, Culture, Public, Immunity, Infection, CFU, CDC, Epidemic, Quarantine, Death, Congress, Professor, CFU-GEMM, Clutch (eggs), United Kingdom, Iliad, Immunization, University of Oxford, Safety, Disease, MD

ILiAD Biotechnologies reported today that its BPZE1 intranasal pertussis vaccine has met the primary endpoint of protection against nasopharyngeal B. pertussis colonization (p=0.03) in the Phase 2b CHAMPION-1 Study.

Key Points: 
  • ILiAD Biotechnologies reported today that its BPZE1 intranasal pertussis vaccine has met the primary endpoint of protection against nasopharyngeal B. pertussis colonization (p=0.03) in the Phase 2b CHAMPION-1 Study.
  • The CHAMPION-1 Phase 2b Human Challenge study is a randomized, double-blind, placebo-controlled study of BPZE1 vaccine in healthy adults.
  • The study has a primary objective to demonstrate that prior immunization with BPZE1 protects against colonization as evidenced by negative B. pertussis culture following virulent B. pertussis challenge 2–4 months after vaccination.
  • As a result, the preparation method of the B. pertussis challenge dose was modified to achieve the per-protocol adequate inoculum of B. pertussis challenge as specified in the original study protocol.

ILiAD Biotechnologies Announces Publication of BPZE1 Adult Phase 2b Clinical Results in The Lancet

Retrieved on: 
Friday, March 10, 2023
Health, FDA, Infectious Diseases, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Pasteur Institute, Iliad, Vaccine, Bordetella pertussis, Mortality, Safety, Tetanus, Medicine, Public, Doctor of Philosophy, Diphtheria, Disease, Immunity, Vaccination, Manuscript, Cold medicine, Infection, IPL, Pharmaceutical industry, Lancet

ILiAD Biotechnologies, LLC (ILiAD), a vaccine company utilizing its B-Tech technology to develop novel vaccines against infectious diseases, today announced a peer-reviewed publication in The Lancet.

Key Points: 
  • ILiAD Biotechnologies, LLC (ILiAD), a vaccine company utilizing its B-Tech technology to develop novel vaccines against infectious diseases, today announced a peer-reviewed publication in The Lancet.
  • The published research article summarizes the adult Phase 2b clinical study of BPZE1, the most advanced next generation pertussis vaccine.
  • The manuscript titled “Immunogenicity and safety of BPZE1, an intranasal live attenuated pertussis vaccine, versus tetanus–diphtheria– acellular pertussis vaccine: a randomised, double-blind, phase 2b trial” was published in The Lancet on March 10, 2023.
  • “In contrast to Boostrix, BPZE1 demonstrated both protection against attenuated Bordetella pertussis colonization and induction of pertussis-specific mucosal immune responses.

ILiAD Biotechnologies Announces $42.8M Financing Round to Advance BPZE1 Pertussis Vaccine

Retrieved on: 
Tuesday, September 6, 2022
FDA, Health, Infectious Diseases, Clinical Trials, Pharmaceutical, Biotechnology, National Institute, Immunization, Vaccination, Research, Harbor, General partnership, Inserm, LP, Death, Doctor of Philosophy, Vaccine, Disease, Bordetella pertussis, R, Pasteur Institute, Volunteering, Injection, Infection, Human challenge study, Medical research, Investment, Whooping cough, Class D, Centers for Disease Control and Prevention, MD, Fast Track, FDA, Iliad, LLC, Private Securities Litigation Reform Act, Industry, Review, Forward-looking statement, Safe harbor

ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotech company developing the worlds most advanced next generation pertussis vaccine, today announced the closing of a $42.8 million Class D round of financing.

Key Points: 
  • ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotech company developing the worlds most advanced next generation pertussis vaccine, today announced the closing of a $42.8 million Class D round of financing.
  • In addition to funding continued operations, R&D and manufacturing development of BPZE1, the financing will support further clinical studies of the vaccine.
  • The Phase 2b pertussis Human Challenge clinical study is currently enrolling volunteers and will directly measure whether ILiADs candidate vaccine, BPZE1, can prevent nasopharyngeal B. pertussis colonization after direct challenge with wild-type B. pertussis bacteria.
  • In preclinical studies, BPZE1 was able to prevent B. pertussis colonization after wild-type B. pertussis challenge, while acellular pertussis vaccines were not.

ILiAD Biotechnologies Announces Presentation of Additional Positive Data for its Next Generation Pertussis Vaccine at the 13th International Bordetella Symposium

Retrieved on: 
Monday, June 27, 2022
Biotechnology, Infectious Diseases, Health, Pharmaceutical, Clinical Trials, Review, University, Research, Iliad, Harbor, Death, Sinusitis, Immunization, Industry, Immunogenicity, Infection, LLC, Investment, Whooping cough, Private Securities Litigation Reform Act, Safety, Centers for Disease Control and Prevention, Vaccine, Vaccination, Twitter, Safe harbor, Bordetella pertussis, Forward-looking statement

According to U.S. Centers for Disease Control and Prevention, pertussis affects approximately 16 million people each year globally, accounting for nearly 200,000 deaths.

Key Points: 
  • According to U.S. Centers for Disease Control and Prevention, pertussis affects approximately 16 million people each year globally, accounting for nearly 200,000 deaths.
  • Pertussis is highly contagious, and an infected person can transmit B. pertussis to as many as 15 other people.
  • ILiAD Biotechnologies is utilizing its B-Tech technology to develop next generation vaccines to prevent infectious diseases and improve lives.
  • Its lead candidate, BPZE1, is the most advanced next generation vaccine for immunization against pertussis (whooping cough), a lethal disease caused by Bordetella pertussis.

Outlook on the Macrolide Antibiotics Global Market to 2027 - Focus on Azithromycin, Clarithromycin, Erythromycin, Fidaxomicin and Telithromycin - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 12, 2022
Health, Pharmaceutical, Macrolide, Erythromycin, Bacillary angiomatosis, Azithromycin, Skin, Dermatology, Bordetella pertussis, Government, Food and Drug Administration Safety and Innovation Act, Toxoplasmosis, Infection, Taxation of Chargeable Gains Act 1992, Dermatologic Clinics, The Pew Charitable Trusts, Mycoplasma pneumonia, CAGR, Pew, Clarithromycin, Pfizer, Pig, Pharmaceutical industry, Marketing

The global macrolide antibiotics market is anticipated to grow at a considerable CAGR during the forecast period.

Key Points: 
  • The global macrolide antibiotics market is anticipated to grow at a considerable CAGR during the forecast period.
  • The global macrolide antibiotics market is segmented based on drugs, route of administration, indication and end-user.
  • Analysis of regional regulations and other government policies impacting the global Macrolide antibiotics market.
  • Insights about market determinants that are stimulating the global macrolide antibiotics market.

Intravacc signs an exclusive license agreement with Zhifei Lvzhu Biopharmaceutical to commercialize Avacc 3 - an OMV based whooping cough vaccine

Retrieved on: 
Monday, May 2, 2022
Diarrhea, WHO, R, Protein, Antigen, OMV, Vaccine, Death, Infection, Fever, Tetanus, Shigellosis, Recombinant, Whooping cough, COVID-19, CHO, Bacteria, Pneumonia, Toxicity, Technology, University, Toxicology, Cough, China Biologic Products, Profile, Vomiting, SZSE, Meningitis, Respiratory disease, Marketing, Bill & Melinda Gates Foundation, Influenza, DTP, CDMO, Immunology, Diagnosis, Bordetella pertussis, DPT, Disease, Denis Favier, Pharmaceutical industry, Trevor Flugge, Diphtheria, Haemophilus influenzae

Under the terms of this agreement Zhifei Lvzhu will receive an exclusive license for the Chinese territory and non-exclusive for Africa, South America and selected Asian countries.

Key Points: 
  • Under the terms of this agreement Zhifei Lvzhu will receive an exclusive license for the Chinese territory and non-exclusive for Africa, South America and selected Asian countries.
  • Intravacc's Avacc 3, a homologous Bordetella pertussis candidate vaccine based on Intravacc's OMV platform, induces a strong systemic immune response.
  • Since 2008, over 110 million doses of vaccines producedby Zhifei Lvzhu have being given to people needed worldwide.
  • Zhifei Lvzhu is a wholly owned subsidiary of ChongqingZhifei Biological ProductsCo., Ltd. (SZSE: 300122, "Zhifei" for short), a leading vaccine supplier and service provider globally.

Intravacc signs an exclusive license agreement with Zhifei Lvzhu Biopharmaceutical to commercialize Avacc 3 - an OMV based whooping cough vaccine

Retrieved on: 
Monday, May 2, 2022
Diarrhea, WHO, R, Protein, Antigen, OMV, Vaccine, Death, Infection, Fever, Tetanus, Shigellosis, Recombinant, Whooping cough, COVID-19, CHO, Bacteria, Pneumonia, Toxicity, Technology, University, Toxicology, Cough, China Biologic Products, Profile, Vomiting, SZSE, Meningitis, Respiratory disease, Marketing, Bill & Melinda Gates Foundation, Influenza, DTP, CDMO, Immunology, Diagnosis, Bordetella pertussis, DPT, Disease, Denis Favier, Pharmaceutical industry, Trevor Flugge, Diphtheria, Haemophilus influenzae

Under the terms of this agreement Zhifei Lvzhu will receive an exclusive license for the Chinese territory and non-exclusive for Africa, South America and selected Asian countries.

Key Points: 
  • Under the terms of this agreement Zhifei Lvzhu will receive an exclusive license for the Chinese territory and non-exclusive for Africa, South America and selected Asian countries.
  • Intravacc's Avacc 3, a homologous Bordetella pertussis candidate vaccine based on Intravacc's OMV platform, induces a strong systemic immune response.
  • Since 2008, over 110 million doses of vaccines producedby Zhifei Lvzhu have being given to people needed worldwide.
  • Zhifei Lvzhu is a wholly owned subsidiary of ChongqingZhifei Biological ProductsCo., Ltd. (SZSE: 300122, "Zhifei" for short), a leading vaccine supplier and service provider globally.